Clinical Trial Detail

NCT ID NCT02089685
Title Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

renal cell carcinoma

melanoma

Therapies

Ipilimumab

Peginterferon alfa-2b

Pembrolizumab

Age Groups: adult

No variant requirements are available.